Durable second complete remissions with oral melphalan in hypocellular Acute Myeloid Leukemia and Refractory Anemia with Excess Blast with normal karyotype relapsing after intensive chemotherapy

Leukemia Research Reports

Volumn 2, Issue 1, 2013, Pages 9-11

  Whittle, Annika M ^a   Feyler, Sylvia ^b   Bowen, David T ^a  

^a ST JAMES S INSTITUTE OF ONCOLOGY   (United Kingdom)

^b CALDERDALE AND HUDDERSFIELD NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Acute Myeloid Leukemia; Melphalan; Myelodysplastic syndromes; Refractory Anemia with Excess Blasts

Indexed keywords

AMSACRINE; CLOFARABINE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GEMTUZUMAB; MELPHALAN; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG RESPONSE; FEMALE; HUMAN; KARYOTYPE; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LOW DRUG DOSE; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; REFRACTORY ANEMIA WITH EXCESS BLASTS; UNSPECIFIED SIDE EFFECT;

EID: 84878370732     PISSN: 22130489     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lrr.2012.10.001     Document Type: Article

References (6)

1. Omoto E, Deguchi S, Isokawa M, Takaba S, Kojima K, Yano T, et al. Low-dose melphalan is an effective and low-cost treatment for high- risk myelodysplastic syndromes with hypoplastic marrow. Blood 1996, 88:2312.
2. Gologan R, Ostroveanu D, Gioada L, Iacob V. Remission induction in elderly acute myeloid leukemia by low-dose melphalan. Romanian Journal of Internal Medicine 2003, 41(1):67-73.
3. Anargyrou K, Vaiopoulos G, Terpos E, Tsironi M, Konstantopoulos K, Samarkos M, et al. Low dose melphalan is a treatment option in elderly patients with high risk myelodysplastic syndrome or secondary acute myeloblastic leukaemia. Haematologia (Budap) 2002, 32(2):169-173.
4. Denzlinger C, Bowen D, Benz D, Gelly K, Brugger W, Kanz L. Low-dose melphalan induces favourable responses in elderly patients with high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia. British Journal of Haematology 2000, 108(1):93-95.
5. Kerr R, Cunningham J, Bowen DT. Low-dose melphalan in elderly acute myeloid leukaemia: complete remissions but resistant relapse with therapy-related karyotypes. Leukemia 2000, 14(5):953.
6. Robak T, Szmigielska-Kaplon A, Urbanska-Rys H, Chojnowski K, Wrzesien-Kus A. Efficacy and toxicity of low-dose melphalan in myelodysplastic syndromes and acute myeloid leukemia with multilineage dysplasia. Neoplasma 2003, 50(3):172-175.